Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. on January 19, 2016. The report discloses the publication of preclinical data regarding the company's investigational drug, CERC-301. CERC-301 is an oral, NR2B-specific NMDA antagonist being developed as an adjunctive treatment for patients with major depressive disorder who have not responded adequately to current antidepressants.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a scientific publication event.
Material Changes
There are no financial material changes reported in this filing. The material event is the publication of a study in the December issue of the Journal of Pharmacology Research & Perspectives titled "Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist."
Outlook, Risks, and Management Commentary
- Management Commentary: The company announced that the published preclinical data suggests antidepressant activity for CERC-301 in a preclinical model.
- Regulatory Status: The information is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
- Risks and Contingencies: The filing does not explicitly list new risks or contingencies, though the data remains at the preclinical stage.
Key Facts for Investor Verification
- Verify the full text of the press release (Exhibit 99.1) for detailed study results.
- Confirm the publication details in the Journal of Pharmacology Research & Perspectives (December issue).
- Review subsequent filings for updates on the clinical development timeline of CERC-301.
- Note that this filing contains no financial statements or liquidity updates.